AllianceBernstein’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-131,235
| Closed | -$13.4M | – | 3208 |
|
|
2023
Q2 | $13.4M | Buy |
131,235
+62,262
| +90% | +$5.89M | 0.01% | 996 |
|
|
2023
Q1 | $6.27M | Sell |
68,973
-44,366
| -39% | -$2.6M | ﹤0.01% | 1309 |
|
|
2022
Q4 | $4.31M | Buy |
113,339
+78,439
| +225% | +$2.7M | ﹤0.01% | 1499 |
|
|
2022
Q3 | $877K | Hold |
34,900
| – | – | ﹤0.01% | 2363 |
|
|
2022
Q2 | $1.06M | Buy |
34,900
+800
| +2% | +$23.9K | ﹤0.01% | 2312 |
|
|
2022
Q1 | $1.12M | Buy |
34,100
+100
| +0.3% | +$2.97K | ﹤0.01% | 2384 |
|
|
2021
Q4 | $897K | Sell |
34,000
-200
| -0.6% | -$15.5K | ﹤0.01% | 2511 |
|
|
2021
Q3 | $3.44M | Hold |
34,200
| – | – | ﹤0.01% | 1815 |
|
|
2021
Q2 | $4.84M | Buy |
34,200
+24,931
| +269% | +$2.82M | ﹤0.01% | 1639 |
|
|
2021
Q1 | $924K | Sell |
9,269
-2,681
| -22% | -$313K | ﹤0.01% | 2445 |
|
|
2020
Q4 | $1.48M | Sell |
11,950
-100
| -0.8% | -$13.1K | ﹤0.01% | 2139 |
|
|
2020
Q3 | $1.17M | Buy |
12,050
+650
| +6% | +$81.2K | ﹤0.01% | 2111 |
|
|
2020
Q2 | $1.78M | Sell |
11,400
-34,830
| -75% | -$5.29M | ﹤0.01% | 1907 |
|
|
2020
Q1 | $6.67M | Buy |
46,230
+400
| +0.9% | +$77.2K | ﹤0.01% | 1060 |
|
|
2019
Q4 | $9.37M | Buy |
45,830
+20,030
| +78% | +$3.65M | 0.01% | 1116 |
|
|
2019
Q3 | $2.07M | Hold |
25,800
| – | – | ﹤0.01% | 1895 |
|
|
2019
Q2 | $2.43M | Sell |
25,800
-500
| -2% | -$43.2K | ﹤0.01% | 1851 |
|
|
2019
Q1 | $2.25M | Buy |
26,300
+2,800
| +12% | +$232K | ﹤0.01% | 1827 |
|
|
2018
Q4 | $1.32M | Sell |
23,500
-100
| -0.4% | -$6.11K | ﹤0.01% | 2066 |
|
|
2018
Q3 | $1.93M | Buy |
23,600
+5,700
| +32% | +$402K | ﹤0.01% | 1969 |
|
|
2018
Q2 | $626K | Buy |
17,900
+1,800
| +11% | +$54.8K | ﹤0.01% | 2531 |
|
|
2018
Q1 | $330K | Buy |
16,100
+1,900
| +13% | +$48.9K | ﹤0.01% | 2663 |
|
|
2017
Q4 | $402K | Hold |
14,200
| – | – | ﹤0.01% | 2604 |
|
|
2017
Q3 | $442K | Hold |
14,200
| – | – | ﹤0.01% | 2617 |
|
|
2017
Q2 | $449K | Buy |
14,200
+3,200
| +29% | +$78.7K | ﹤0.01% | 2652 |
|
|
2017
Q1 | $249K | Hold |
11,000
| – | – | ﹤0.01% | 2782 |
|
|
2016
Q4 | $240K | Hold |
11,000
| – | – | ﹤0.01% | 2826 |
|
|
2016
Q3 | $290K | Buy |
+11,000
| New | +$218K | ﹤0.01% | 2707 |
|
Other funds holding RETA
AllianceBernstein's RETA Position: Q3 2023 in Review
AllianceBernstein sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 131,235 shares — an estimated $13.4M sold.
AllianceBernstein first reported a position in RETA in Q3 2016 and held it in 28 quarters. The position peaked at $13.4M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- AllianceBernstein reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- AllianceBernstein sold 131,235 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $13.4M.
- AllianceBernstein first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2016 and held it in 28 quarters.
- AllianceBernstein's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $13.4M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on AllianceBernstein's 13F filing for Q3 2023, filed 14 Nov 2023.